$VIRX
Viracta Therapeutics, Inc.

2015 Q3 Form 10-Q Financial Statement

#000156459016027314 Filed on November 03, 2016

View on sec.gov

Income Statement

Concept 2015 Q3
Revenue $683.0K
YoY Change -20.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.990M
YoY Change -44.81%
% of Gross Profit
Research & Development $5.259M
YoY Change -24.21%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $9.253M
YoY Change -34.68%
Operating Profit -$8.570M
YoY Change -35.62%
Interest Expense $233.0K
YoY Change -40.41%
% of Operating Profit
Other Income/Expense, Net $1.782M
YoY Change -209.8%
Pretax Income -$7.020M
YoY Change -54.21%
Income Tax
% Of Pretax Income
Net Earnings -$7.021M
YoY Change -54.19%
Net Earnings / Revenue -1027.96%
Basic Earnings Per Share -$0.56
Diluted Earnings Per Share -$0.56
COMMON SHARES
Basic Shares Outstanding 12.46M
Diluted Shares Outstanding 12.46M

Balance Sheet

Concept 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.50M
YoY Change -31.77%
Cash & Equivalents $16.80M
Short-Term Investments $13.70M
Other Short-Term Assets $800.0K
YoY Change -38.46%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $31.30M
YoY Change -31.95%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $31.30M
Total Long-Term Assets $0.00
Total Assets $31.30M
YoY Change -32.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.800M
YoY Change 133.16%
Accrued Expenses $6.100M
YoY Change -36.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $5.900M
YoY Change -40.4%
Total Short-Term Liabilities $16.14M
YoY Change -56.72%
LONG-TERM LIABILITIES
Long-Term Debt $1.900M
YoY Change 11.76%
Other Long-Term Liabilities $1.200M
YoY Change -64.71%
Total Long-Term Liabilities $3.100M
YoY Change -39.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.14M
Total Long-Term Liabilities $3.100M
Total Liabilities $19.30M
YoY Change -54.48%
SHAREHOLDERS EQUITY
Retained Earnings -$547.8M
YoY Change 5.07%
Common Stock $559.9M
YoY Change 6.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.06M
YoY Change
Total Liabilities & Shareholders Equity $31.32M
YoY Change -32.0%

Cashflow Statement

Concept 2015 Q3
OPERATING ACTIVITIES
Net Income -$7.021M
YoY Change -54.19%
Depreciation, Depletion And Amortization $0.00
YoY Change -100.0%
Cash From Operating Activities -$9.650M
YoY Change -23.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $5.560M
YoY Change -29.26%
Cash From Investing Activities $5.560M
YoY Change -29.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 590.0K
YoY Change -147.2%
NET CHANGE
Cash From Operating Activities -9.650M
Cash From Investing Activities 5.560M
Cash From Financing Activities 590.0K
Net Change In Cash -3.500M
YoY Change -41.08%
FREE CASH FLOW
Cash From Operating Activities -$9.650M
Capital Expenditures $0.00
Free Cash Flow -$9.650M
YoY Change -22.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11000
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
20878670
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
19544000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
558000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
46988000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26886000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
16459000
CY2016Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3369000
CY2016Q3 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
18431000
CY2016Q3 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
1000
CY2016Q3 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
5000
CY2016Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3369000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14480000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11945000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.10
snss Write Off Of Debt Discount Upon Note Repayment
WriteOffOfDebtDiscountUponNoteRepayment
27000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-3543000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
282000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-422000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
73000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1387000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-319000
snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-1203000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-119000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-796000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1091000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-296000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1830000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2319000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28990000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-29455000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
24352000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
31450000
snss Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
490000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
1123000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
7098000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
15000000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
830000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1642000
snss Payoff Of Notes Payable And Final Payment
PayoffOfNotesPayableAndFinalPayment
7153000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
266000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
21000
snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
18125000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
34000
snss Proceeds From Exercise Of Warrants Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfWarrantsStockOptionsAndStockPurchaseRights
489000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6806000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16972000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21061000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5385000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22186000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16801000
us-gaap Stock Issued1
StockIssued1
4486000
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
536000
us-gaap Other Significant Noncash Transaction Value Of Consideration Given1
OtherSignificantNoncashTransactionValueOfConsiderationGiven1
100000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
39347000
CY2016Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
24300000
snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2016Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1667
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
39358000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of equity and related instruments, debt instruments, revenue recognition, stock-based compensation and clinical trial accounting. </p></div>
CY2016Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
21800000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1998-02-10
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Reverse Split, every six shares of common stock were combined into one share of capital stock. The Reverse Split affected the shares of Company's common stock: (a) outstanding immediately prior to the effective time of the Reverse Split, (b) available for issuance under the Company's equity incentive plans, (c) issuable upon the exercise of outstanding stock options and warrants and (d) issuable upon conversion of the outstanding Series B Preferred Stock. All share and per-share data in our condensed consolidated financial statements and notes thereto give retroactive effect to the Reverse Split for all periods presented.
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2016Q3 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
700000
CY2015Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
700000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5715000
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3267000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5715000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3267000
CY2016Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
21796000
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
19803000
CY2015Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
19555000
CY2016Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
5000
CY2016Q3 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
7305000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
11000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
11649000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
500000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2016Q3 us-gaap Notes Payable
NotesPayable
15000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3749000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4635000
CY2015Q4 snss Marketable Securities Gross Unrealized Losses
MarketableSecuritiesGrossUnrealizedLosses
11000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
19803000

Files In Submission

Name View Source Status
0001564590-16-027314-index-headers.html Edgar Link pending
0001564590-16-027314-index.html Edgar Link pending
0001564590-16-027314.txt Edgar Link pending
0001564590-16-027314-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2016110316534395412259.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10q_20160930.htm Edgar Link pending
snss-20160930.xml Edgar Link completed
snss-20160930.xsd Edgar Link pending
snss-20160930_cal.xml Edgar Link unprocessable
snss-20160930_def.xml Edgar Link unprocessable
snss-20160930_lab.xml Edgar Link unprocessable
snss-20160930_pre.xml Edgar Link unprocessable
snss-ex311_358.htm Edgar Link pending
snss-ex312_357.htm Edgar Link pending
snss-ex321_356.htm Edgar Link pending